These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11233234)

  • 1. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
    Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
    Razumov SV; Egorov AA
    Urologiia; 2007; (3):47-50. PubMed ID: 17724829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospective follow-up of 3,228 patients suffering from clinical benign prostatic hyperplasia (BPH) treated for 3 years wi alfuzosin in general practice. BPH Group in General Practice].
    Lukacs B; Grange JC; Comet D; Mc Carthy C
    Prog Urol; 1999 Apr; 9(2):271-80. PubMed ID: 10370951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.